AZD2014 is tolerable clinically, and in paired tumor biopsies was shown to inhibit S6 phosphorylation [13], although a recent Phase 2 trial in metastatic VEGF-inhibitor refractory RCC was halted early when AZD2014 was found to be inferior to everolimus [50]. This evidence concerns the gene VEGFA and neoplasm.